All News

joint.wrist_.pain_.CTS_.Carpal.jpg

Steroid Injection Superior to Splinting in Carpal Tunnel Syndrome

d Jack Cush, MD

Lancet has published a comparative effectiveness study examining the the value of night splints (conservative treatment) vs local injection for patients with carpal tunnel syndrome.

Read Article
arthroscopic.knee_.jpg

Low Risk of Serious Complications with Meniscectomy

d Jack Cush, MD

Lancet reports on the safety of over 1 million arthroscopic partial meniscectomies done in the United Kingdom and found a low overall risk in the first 90 days.

They examined Hospital Episode Statistics on  1,088,782 arthroscopic partial meniscectomies (1997-2017); 699 965 of which were eligible for analysis. They sought to identify complications occurring in the 90 days after the index procedure.

Read Article
MAS.jpg

First FDA Approved Drug for HLH

d RheumNow

The first drug specifically for primary hemophagocytic lymphohistiocytosis (HLH) was approved today, the FDA announced.

Read Article
Could routine use of hydroxychloroquine reduce the rate of serious infections in immunosuppressed patients? A modest to moderate risk reduction noted in two large SLE cohort studies. https://t.co/pssLrteRRq

Links:

Dr. John Cush RheumNow ( View Tweet)

2018 NRMP report shows Rheumatology as one of the most competitive fellowships with 313 applicants for 221 positions - 147 filled by US grads and 69 by FMGs. https://t.co/xRmMyA2yCy

Links:

Dr. John Cush RheumNow ( View Tweet)

Clinical Trials Benchmark for Biosimilar Development is one of several educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow. https://t.co/1vmnEJqOSi

Links:

Dr. John Cush RheumNow ( View Tweet)

J Rheum (Ward et al) reports that the minimal clinically important improvement (MCII) of RAPID-3 was –3.8. https://t.co/UxCOeMl52g

Links:

Dr. John Cush RheumNow ( View Tweet)

The "Type" of person you are often is displayed with how you manage authority

Dr. John Cush RheumNow ( View Tweet)

CORRECTION: mm! Guidelines on CT pulm nodules-no F/U needed for solid nodules <6mm in low risk pts (age,smoking, morphology); but larger (6-8mm), suspicious nodules should have 6 & 12 mos F/U images. Some 8cm or more nodules require more freq assessments https://t.co/Nl6zV3VQg1

Links:

Dr. John Cush RheumNow ( View Tweet)

“This is not your responsibility but it is your problem.” — Cheryl Strayed I believe the converse is more important to what we need to teach our patients - "This is not just your problem, this is now your responsibility"

Dr. John Cush RheumNow ( View Tweet)

Safety and Immunogenicity is one of nine educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow. https://t.co/1vmnEJqOSi

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA Approves Gamifant (emapalumab-lzsg) for Primary Hemophagocytic Lymphohistiocytosis https://t.co/YALlc0XdKh

Links:

Dr. John Cush RheumNow ( View Tweet)

Are you a US rheumatologist interested in what the midterm election results mean for us? 100 members of the next Congress are NEW and we need to meet them! Please invest in #RheumPAC NOW. Help advance arthritis research, reform step therapy & other causes! https://t.co/pcRkh6eLfJ

Links:

Angus Worthing MD AngusWorthing ( View Tweet)

Sudden discontinuation of duloxetine may have Adverse Events in up to 44% - dizziness, nauseam headache, paresthesia, vomiting, irritability, nightmares. Instead, its rec to gradually reduce dose over 2 weeks before D/C of duloxetine.https://t.co/aSGU0CVldB

Links:

Dr. John Cush RheumNow ( View Tweet)

New Guidelines on CT pulm nodules-no F/U needed for solid nodules <6cm in low risk pts (age, smoking, morphology); but larger (6-8cm), suspicious nodules should have 6 and 12 mos F/U images. Some 8cm or more nodules require more freq assessments https://t.co/Nl6zV3VQg1

Links:

Dr. John Cush RheumNow ( View Tweet)

The Next Best Meeting in Rheumatology is coming - RHEUMNOW LIVE - March 22-24 2019 in beautiful downtown Fort Worth. Short Lectures, interactive sessions, Q&A panels, TED (like) Talks, digital, streaming and much more. You dont want to miss this meeting! https://t.co/5TVg0Frsbf

Links:

Dr. John Cush RheumNow ( View Tweet)

79 pts Ultrasound evidence of gout (tophus or double contour sign) @ knee or MTP1 were given ULT for 6 mos. Those achieving very low uric acid levels showed US decrease in tophus (r = 0.54) and double contour sign disappearance (r=−0.59) https://t.co/4W0EX8swDo

Links:

Dr. John Cush RheumNow ( View Tweet)

Large claims analysis shows that lipid screening was suboptimal (37%) among RA patients but was higher when RA patients visited a rheumatologist and a non-rheumatology clinicians (~55%). https://t.co/S4Op22LOoY

Links:

Dr. John Cush RheumNow ( View Tweet)

A step-by-step guide to academic publication for young investigators #SciComm #PhD #postdoc #scientist https://t.co/yEnd2xJelZ https://t.co/kyZiQSX7L9

Links:

Immunometabolism Network ImmunoMet ( View Tweet)
"Therapeutic Update: Biosimilars in Rheumatology" video series features nine experts talking about biosimilars, sponsored by Sandoz, Inc. Visit RheumNow to watch: https://t.co/1vmnEJqOSi #biosimilars

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×